Marburg Virus Disease: a Summary for Clinicians
Contenu
Click for External Resource*
Click to read full article*
*The link above may share a zip file (.zip) hosted on repository.netecweb.org. Zip files will download automatically.
*All other links are external and will open in a new window. If you click an external link, you are leaving the NETEC site, and we do not maintain, review, or endorse these materials. See our terms of use.
Files for Download
PIIS1201971220305865.pdfItem Type
PublicationTerms of Use
Voir les documents
Titre
Sujet
Description
Source
Date
Type
Citer ce document
Résumé
Objectives: This article is a summary of countermeasures for Marburg virus disease focusing on pathogenesis, clinical features, and diagnostics, with an emphasis on therapies and vaccines that have demonstrated potential for use in an emergency situation, through their evaluation in nonhuman primates (NHPs) and/or in humans.
Methods: A standardized literature review was conducted on vaccines and treatments for each pathogen, with a focus on human and nonhuman primate data published in the last five years. More detail on the methods used are summarized in a companion methods paper.
Results: We identified six treatments and four vaccine platforms that have demonstrated potential benefit for treating or preventing infection in humans, through their efficacy in NHPs.
Conclusion: We provide succinct summaries of Marburg countermeasures to give the busy clinician a head start in reviewing the literature if faced with a patient with Marburg virus disease. We also provide links to other authoritative sources of information.
Keywords: Ebola virus; Marburg virus; antiviral countermeasure; antiviral therapy; filovirus; treatment; vaccine.
Copyright © 2020. Published by Elsevier Ltd.
Accessibilité
https://doi.org/10.1016/j.ijid.2020.07.042 1201-9712/
2020 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Was this resource helpful?